Macrophage Therapeutics Announces Manocept™ Results in Kaposi’s Sarcoma Studies to Be Presented at the American Associati...
April 15 2015 - 6:45AM
Business Wire
Macrophage Therapeutics, Inc., a subsidiary of Navidea
Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that a
presentation of Manocept™ data from Kaposi’s sarcoma studies is
scheduled at the American Association of Cancer Research (AACR)
Annual Meeting 2015 in Philadelphia, PA from April 18 - 22, 2015.
This research, led by Michael S. McGrath, M.D, Ph.D. and Toby
Maurer, M.D., Kaposi’s sarcoma and HIV experts, at the University
of California San Francisco, highlights both ex vivo and in vivo
results in support of Manocept targeting of macrophages and tumor
cells. Details of the presentation are listed below.
Poster Session:
Therapeutics and Therapeutic Models
Date:
April 22, 2015
Title:
Tumor associated targeting with
Manocept: HIV associated Kaposi’s sarcoma as a model system in
Humans
Authors:
Rongzhen Zhang1*, Frederick O. Cope2, Toby
Maurer1,3, Spencer Behr1, Paige M. Bracci1,3, Michael S.
McGrath1,3
1University of California San Francisco,
San Francisco, CA; 2Navidea Biopharmaceuticals/Macrophage
Therapeutics, Dublin, OH; 3AIDS and Cancer Specimen Resource, San
Francisco, CA. *Presenter
About Macrophage TherapeuticsMacrophage Therapeutics, a
newly created subsidiary of Navidea Biopharmaceuticals, Inc.
(NAVB), is developing therapeutics using the patented Manocept
immunotherapy platform licensed from Navidea to target over-active
macrophages implicated in cancer, cardiovascular, central nervous
system, autoimmune, antiviral, and skin diseases. Manocept
specifically targets CD206, or mannose receptor prevalent on
over-active macrophages. The technology enables highly specific
targeted delivery of active (either existing or yet to be
developed) agents that can modulate the activity of over-active
macrophages that have been implicated in many diseases. Targeted
delivery should significantly enhance a given compound’s efficacy
and safety.
About Navidea Biopharmaceuticals Inc.Navidea
Biopharmaceuticals, Inc. (NYSE MKT:NAVB) is a commercial stage
precision medicine company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™,
NAV4694, and NAV5001, to help identify the sites and pathways of
undetected disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and by the EMA in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and
therapeutics, and advancing the Company’s pipeline through global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Associate
Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2024 to May 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From May 2023 to May 2024